✦ LIBER ✦

DEGARELIX COMPARED TO LEUPROLIDE DEPOT 7.5 MG IN A 12- MONTH RANDOMISED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY IN PROSTATE CANCER PATIENTS

✍ Scribed by L. Boccon-Gibod; L. Klotz; H. Schröder; C. Andreou; B.E. Persson; P. Cantor; J.K. Jensen; T. Kold Olesen

Book ID: 119618865
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 73 KB
Volume: 7
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(08)60533-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and safety of degarelix: a

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

✍ Laurence Klotz; Laurent Boccon-Gibod; Neal D. Shore; Cal Andreou; Bo-Eric Persso 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB

Re: The Efficacy and Safety of Degarelix

Re: The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer

✍ Dieter Jocham; Christian Doehn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Cardiovascular Safety of Degarelix: Resu

Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer

✍ Smith, Matthew R.; Klotz, Laurence; Persson, Bo-Eric; Olesen, Tine Kold; Wilde, 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 226 KB

582 CARDIOVASCULAR SAFETY OF DEGARELIX:

582 CARDIOVASCULAR SAFETY OF DEGARELIX: RESULTS FROM A 12-MONTH, COMPARATIVE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III TRIAL IN PROSTATE CANCER PATIENTS

✍ Klotz, Laurence; Smith, Matthew; Persson, Bo-Eric; Olesen, Tine Kold; Wilde, Art 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 45 KB

Changes in alkaline phosphatase levels i

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study

✍ Fritz H. Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D. S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

Changes in alkaline phosphatase levels i

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study

✍ Fritz H. Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D. S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

Study Type – Therapy (RCT) Level of Evidence 1b ## OBJECTIVE To compare the activity of degarelix, a new gonadotrophin‐releasing hormone (GnRH) blocker, with leuprolide depot 7.5 mg in the control of total serum alkaline phosphatase (S‐ALP) levels in patients with prostate cancer. ## PATIENTS AND